This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): levocetirizine, Xusal, Xysal
Description: Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors. Binding studies revealed that levocetirizine has high affinity for human H1-receptors. Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.
UCB and Sepracor (now Dainippon Sumitomo)
In June 1999, Sepracor announced a licensing agreement with UCB relating to levocetirizine. Under the terms of the agreement, Sepracor has exclusively licensed to UCB all of Sepracor's issued patents and pending patent applications regarding levocetirizine in Europe and all other countries, except the United States andJapan. UCB pays Sepracor royalties upon first product sale, and royalties escalate upon achievement of sales volume milestones.
In February 2006, UCB and Sepracor announced an restructuring of their license agreement. Under this amendment, Sepracor has exclusively licensed to UCB all of Sepracor's patents and patent applications in the United States regarding levocetirizine and royalties will be payable to Sepracor on U.S. sales of levocetirizine products.
In September 2009, Dainippon Sumitomo Pharma (DSP) and Sepracor announced that they entered into a definitive agreement pursuant to which DSP will acquire...See full deal structure in Biomedtracker
Partners: Sumitomo Dainippon Pharma Co., Ltd. Sanofi GlaxoSmithKline plc
Additional information available to subscribers only: